JR...In the short term, I expect Amarin to get approval for Vascepa in China along with a decision on remunerations for Vascepa in China at low prices...i.e. through Amazon's partner. Eddingpharm...This may lead Amarin to issue an AG in the U.S....Amarin,with the added income from sales in China and from the U.S. AG, will be able to have the assets to market Vascepa globally at low prices and high volumes...I have long thought that this is the future path for Vascepa.
If there is any plan on releasing a new/cheaper form of Brand V using the MND-2119 formula I doubt we'll see an AG. You dont toss your Brand name that's on the market in the dumpster for an AG for a few years, only to try and resurrect that brand name later with a change in formulation.